To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
A OrlandiL MastrantoniE BriaG TortoraPublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
Keyphrases